Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162463 | 0.77 | KDM4E (0.69) | ALDH1A1MAPTKMT2ATDP1POLB | |
| SCHEMBL30941613 | 0.77 | KDM4E (0.69) | ALDH1A1MAPTKMT2ATDP1POLB | |
| SCHEMBL2252130 | 0.76 | MAPK1 (0.46) | ALDH1A1MAPTKMT2ATDP1HSD17B10 | |
| SCHEMBL4078648 | 0.76 | POLB (0.44) | PKMALDH1A1MAPTKMT2ATDP1 | |
| SCHEMBL18669167 | 0.75 | GAA (0.60) | ALDH1A1MAPTKMT2ATDP1HSD17B10 | |
| Hydrochloric Acid SCHEMBL31169322 | 0.75 | KDM4E (0.67) | ALDH1A1MAPTKMT2ATDP1POLB | |
| Hydrazine SCHEMBL28289723 | 0.74 | HSD17B10 (0.65) | ALDH1A1MAPTKMT2ATDP1HSD17B10 | |
| SCHEMBL9030804 | 0.72 | SLC6A3 (0.61) | KMT2ASLC6A3MEN1 | |
| SCHEMBL10263526 | 0.71 | ALDH1A1 (0.63) | ALDH1A1MAPTKMT2ATDP1POLB | |
| SCHEMBL1206178 | 0.70 | KMT2A (0.58) | ALDH1A1MAPTKMT2APOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-21 | — | — | US | disclosed |
| WO-2022067063-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | PKM 3053/4885ALDH1A1 4014/4885MAPT 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.